Full Press Release Details
Biopharma Names Charles J. Casamento to the Board of Directors
CALIFORNIA, May 4, 2023 /PRNewswire/ - GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology
company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE
platform, has named Charles J. Casamento to fill a vacant seat on the Board and to serve as a member of the Audit Committee of the Board,
the Compensation Committee of the Board and the Nominating and Corporate Governance Committee of the Board as of May 1, 2023. Concurrently,
Alan Urban resigned as a member of the Board of Directors (the "Board") in order to pursue new career endeavors.
Breen, Executive Chairman and interim Chief Executive Officer commented on the occasion, "We are delighted to have someone of Mr.
Casamento's caliber join GT Biopharma's board at this critical stage of pipeline development. We look forward to leveraging
his experience and relationships across pertinent matters in addition to his participation across several board committees. Additionally,
we also would like to thank Mr. Urban for his guidance as we now transition into a clinical stage biotechnology company behalf of management
and the board we wish Mr. Casamento well in this new position in addition to Mr. Urban in his next role."
Charles J. Casamento's Background
is currently executive director and principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and
partnerships between biotechnology companies and pharmaceutical companies, since 2007. Mr. Casamento's career in healthcare spans
more than 35 years, where he was a founder or had held senior management roles at various biopharmaceutical companies including Osteologix
Inc., Questcor Pharmaceuticals, Inc., RiboGene, Inc., Interneuron Pharmaceuticals (Indevus), Genzyme Corporation,
amongst other companies.
also serves on the board of directors of the following NASDAQ listed companies: Eton Pharmaceuticals, Inc., First Wave
Biopharma, Inc., PaxMedica, Inc., and Relmada Therapeutics, Inc. During his career he has served on the boards of
fourteen Biotech/Pharma companies and has also been a director and vice chairman of The Catholic Medical Missions Board, a large not-for-profit
organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is
on the Science Council of Fordham University.
holds a bachelor's degree in Pharmacy from Fordham University and an MBA from Iona University and was originally licensed to practice
pharmacy in the states of New York and New Jersey. Mr. Casamento's significant experience in the biotechnology sector make him
a valuable addition to the Board.
Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic
products based on our proprietary TriKE NK cell engager platform. Our TriKE platform is designed to harness and
enhance the cancer killing abilities of a patient's immune system's natural killer cells. GT Biopharma has an exclusive worldwide
license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
For more information, please visit gtbiopharma.com.
statements in this press release may constitute "forward-looking statements" regarding future events and our future results.
All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These
statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs
and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals,"
"projects", "intends," "plans," "believes," "seeks," "estimates,"
"endeavors," "strives," "may," or variations of such words, and similar expressions are intended
to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks,
uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and
adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our
most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other
reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking
statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the
result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and
Exchange Commission.
is a registered trademark owned by GT Biopharma, Inc.